Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
+ 3 more
Nothing from your lists
SunPower Inc. · “On September 17, 2026, Jamie Haenggi, a member of the Board of Directors (the “ Board ”) of SunPower Inc. (the “ Company ”), informed the Company of her decision not to stand for reelection at the Company’s 2026 Annual Meeting of Stockholders (the “ 2026 Annual Meeting ”).”¶1
Metal Sky Star Acquisition Corp · “On September 4, 2026, Metal Sky Star Acquisition Corporation (the “Company”) notified UHY LLP (“UHY”) that UHY would be dismissed as the Company’s independent registered public accounting firm.”¶1
DarkPulse, Inc. · “On September 11, 2026, the Company engaged M&K CPAS, PLLC (" M&K ") to serve as the Company's independent registered public accounting firm.”¶1
Ocean Power Technologies, Inc. · “Effective September 14, 2026, Dr. Philipp Stratmann will step down from his roles as President and Chief Executive Officer and a member of the Board of Directors, by mutual agreement, and will remain available to assist the new leadership team through a transition period.”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
At the Effective Time, Parent issued 25,085,454 shares of Parent Stock and Pre-Funded Warrants to purchase an aggregate of 19,888,093 shares of Parent Common Stock.¶1
Immediately following the Effective Time, legacy Host DI members owned approximately 96.4% of Parent’s issued and outstanding Common Stock, and Parent Common Stock began trading under “HOST” on September 18, 2026.¶2¶3
Host DI entered into a 15-year lease to provide 43 MW of critical IT load capacity, with aggregate base-term contracted rent of approximately $1.25 billion, expected to commence in the first quarter of 2027.¶4
Host DI reported no material revenue from operations and net losses of $3,703,223 and $5,039,396 for the three and six months ended July 31, 2026, respectively.
Jamie Haenggi will continue serving as a director until the 2026 Annual Meeting, and her decision was not the result of disagreement with the Company or Board.¶1¶2
SunPower set November 2, 2026 for a virtual 2026 Annual Meeting, with September 18, 2026 as the record date for stockholders entitled to vote.¶3
Stockholder proposals and director nominations for the 2026 Annual Meeting must be delivered to or received by the Company by September 28, 2026.¶4¶5
Amesite Inc. will hold its next Annual Meeting of Stockholders on Thursday, December 10, 2026.¶1
Stockholder proposals, director nominations, and other business notices must be received by the Company’s Secretary no later than September 27, 2026.¶2¶3
Written notice required under Rule 14a-19 for proxy solicitation supporting director nominees must be received by October 13, 2026, in addition to advance notice requirements.¶4¶5
On September 17, 2026, Aethlon, its merger subsidiaries and North Immunology entered into a merger agreement under which North Immunology will combine with the subsidiaries.¶1
The Private Placement comprises approximately $146 million in cash proceeds and approximately $34 million from contributed convertible promissory notes.¶2
At closing, pre-Merger North Immunology stockholders are expected to own approximately 95.25% of the combined company and pre-Merger Company stockholders approximately 4.75%.¶3
The Merger requires stockholder, Nasdaq and regulatory approvals, proceeds of not less than $175,000,000, and may be terminated if not completed by June 17, 2027.¶4¶5
On September 4, 2026, the Company notified UHY LLP that UHY would be dismissed as its independent registered public accounting firm, effective September 4, 2026.¶1
UHY’s audit reports for the fiscal years ended December 31, 2025 and 2024 included explanatory paragraphs relating to substantial doubt about the Company’s ability to continue as a going concern.¶2
Through September 4, 2026, the Company reported no disagreements with UHY and no reportable events other than material weaknesses in internal control over financial reporting.¶3
As of the filing date, the Company had not engaged a new independent accounting firm for the fiscal year ending December 31, 2026.¶4
On September 11, 2026, DarkPulse dismissed Boladale Lawal & Co. as its independent registered public accounting firm and began transitioning to a new auditor.¶2¶3
The dismissals and engagements of the independent registered public accounting firms were ratified by DarkPulse’s board of directors on September 14, 2026.¶4¶5
BLC’s reports on the consolidated financial statements for the fiscal years ended December 31, 2025 and December 31, 2024 each contained an explanatory paragraph expressing substantial doubt about the Company’s ability to continue as a going concern.¶6
M&K will audit DarkPulse’s consolidated financial statements for the year ending December 31, 2026 and review unaudited quarterly financial information for the three- and nine-month periods ended September 30, 2026.¶1
On September 14, 2026, Philipp Stratmann stepped down as President, Chief Executive Officer and a member of the Board by mutual agreement.¶2¶1
Tracy Pagliara was appointed Acting President and Chief Executive Officer and a director, effective September 10, 2026.¶3¶4
Jason Weed was appointed Chief Operating Officer effective September 14, 2026, with responsibility for commercial sales, operations, technology and innovation.¶5¶6
Pagliara’s new employment agreement provides an annual base salary not to exceed $400,000 and a restricted stock unit grant of 75,000 shares.¶7
Weed’s employment agreement provides an annual base salary not to exceed $400,000 and a restricted stock unit grant of 50,000 shares.¶8
On September 9, 2026, the Company acquired all issued and to be issued share capital of Barinthus Bio, making it a wholly-owned subsidiary.¶2¶3
On September 15, 2026, the Company offered to purchase up to an aggregate purchase price of $15 million of common stock at $6.6609 per Share.¶4¶5
In connection with the Transaction and Offer, the Company adopted amended and restated charter and bylaws, effective September 9, 2026 and September 8, 2026, respectively.¶6¶1
On September 16, 2026, Alaunos Therapeutics’ board approved and adopted amended and restated bylaws effective immediately.¶1
The bylaws changed the stockholder meeting quorum from a majority in voting power to one-third (1/3) in voting power.¶1
The quorum requirement for meetings of the board and its committees remains a majority.¶2
The Company changed its name from “SpringBig Holdings, Inc.” to “SBIG Holdings, Inc.” effective immediately upon filing the amendment on September 16, 2026.¶1¶2
The Board approved an inducement grant of 3,750,000 shares of Series A Preferred Stock to Andrew Glashow and cash compensation of $10,000 per month, contingent on the Certificate of Designation becoming effective.¶3
The Board approved a one-time inducement grant of 250,000 shares of Series A Preferred Stock and cash compensation of $5,000 per month for non-employee directors, contingent on the Certificate of Designation becoming effective.¶4
The Bylaws Amendment replaced references to “SpringBig Holdings, Inc.” and decreased the stockholder-meeting quorum requirement from a majority to one-third (1/3) of voting power.¶5
The Company established Series A Preferred Stock with 5,000,000 authorized shares and 25 votes per share, voting with the Common Stock as a single class.¶6¶7¶8
The Company filed charter amendments providing for a one-for-nine reverse stock split effective at 5:00 p.m. Eastern Time on September 21, 2026, and a par-value decrease effective at 5:01 p.m. Eastern Time that day.¶1¶2
Stockholders entitled to fractional shares will instead receive cash equal to the applicable fraction multiplied by the September 21, 2026 closing price of the Company’s Common Stock, without interest.¶3
The Common Stock will begin split-adjusted trading on September 22, 2026, under CUSIP number 963025721, while the trading symbol will remain unchanged.¶4¶5
As of September 17, 2026, the Company had 5,113,901 shares outstanding and anticipates approximately 568,211 shares post-Reverse Stock Split, without changing relative ownership or voting rights except for fractional-share cash payments.¶6¶7
On September 14, 2026, Surgery Partners completed the disposition of Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health after the purchase agreements became effective.¶2¶3
The company received aggregate consideration of approximately $796.6 million, subject to further adjustments, and intends to use the proceeds primarily to pay down debt.¶4
Surgery Partners received $797 million in gross proceeds and $587 million in net cash proceeds, and updated full-year 2026 revenue guidance to $3.08 billion to $3.18 billion.¶5¶6¶7
On September 17, 2026, Lisata completed its acquisition of Marea pursuant to the Merger Agreement.¶1
Lisata issued Marea stockholders 1,793,129.0 shares of Common Stock and 211,365.213 shares of Series C Preferred Stock, each convertible into 1,000 shares of Common Stock.¶2
Lisata agreed to sell 150,867.995 shares of Series C Preferred Stock for approximately $225 million in a private placement, with closing expected on September 18, 2026.¶3¶4¶5¶6¶7
Following the Financing, pre-transaction Company stockholders held approximately 2.39%, former Marea equityholders held approximately 59.54%, and Investors held approximately 38.07% of Common Stock.¶8
On September 17, 2026, Ted W. Love was appointed to the Board, Josh Lehrer was appointed President and Chief Operating Officer, and David J. Mazzo resigned solely as President while retaining his Chief Executive Officer position.¶9¶10
On September 11, 2026, Axe Compute entered into an agreement to sell all issued and outstanding Helomics shares to DataMeds.¶2
The purchase price consisted of 636,328 DataMeds common shares, representing 19.99% of its outstanding shares, and a convertible promissory note with a principal amount of $1,363,672.¶2
The closing of the transaction occurred simultaneously with the execution and delivery of the Agreement on September 11, 2026.¶3
On September 16, 2026, Rexford Industrial Realty, L.P. and subsidiaries completed the disposition of 22 industrial properties to an affiliate of EQT Real Estate for approximately $1.2 billion.¶2¶1
The Company said it intends to use net proceeds for general corporate purposes, including debt repayment, repurchases of common stock, and internal repositioning and development projects.¶2
Third quarter to date, the Company deployed a portion of disposition proceeds to repay $485 million of debt and repurchase $205 million of common stock.¶3
Rexford Industrial completed $1.5 billion of dispositions year to date, placing the Company within its full-year 2026 disposition guidance range of $1.5 billion to $2.0 billion.¶4
